Loading...
01/11 03:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows a reduction in net loss and operating expenses, but the cash position is weak. The Q&A highlights progress in clinical partnerships and commercialization plans, but uncertainties in FDA approval and lack of financial guidance raise concerns. The absence of new partnerships or positive guidance adjustments tempers optimism, leading to a neutral sentiment.
Operating Expenses $10.5 million (decreased from $13.2 million in 2022) - Decrease mainly due to lower research and development and sales and marketing expenses.
Research and Development Expenses Decreased by approximately $1.6 million - Decrease attributed to the completion of the development of the initial TAEUS product.
Sales and Marketing Expenses Decreased by approximately $609,000 - Mainly due to the departure of the Chief Commercial Officer.
General and Administrative Expenses Decreased by approximately $478,000 - Mainly due to a two-year management bonus write-off and lower professional fees.
Net Loss $10.1 million or $1.58 per share (compared to a net loss of $13.2 million or $4.50 per share in 2022) - Improvement in net loss year-over-year.
Cash and Cash Equivalents $2.8 million as of December 31, 2023 - Reflects the company's liquidity position.
Capital Raised in Q4 2023 $677,000 in gross proceeds from the sale of common stock and $1.1 million from the exercise of warrants - Indicates ongoing efforts to secure funding.
TAEUS System Installation: Installed the TAEUS system at King's College Hospital in the UK, leading a clinical study comparing TAEUS's liver fat assessment accuracy to MRI.
Clinical Studies: Initiated new studies at King's College and University of Michigan to validate TAEUS technology against MRI.
Market Expansion: Expecting commercial sales in Europe, particularly in Germany, the UK, and France, leveraging CE mark and clinical data.
New Market Opportunities: Exploring the U.S. bariatric and obesity management market, expanding addressable market beyond hepatology and endocrinology.
Operational Efficiencies: Operating expenses decreased to $10.5 million in 2023 from $13.2 million in 2022, mainly due to lower R&D and sales/marketing expenses.
Strategic Partnerships: Engaging in collaborations and strategic pathways to expand TAEUS applications beyond liver disease.
Regulatory Risks: ENDRA is currently engaged with the FDA regarding their De Novo application for the TAEUS system. They received an additional information request from the FDA, which included questions about the system's configuration and clinical data. This ongoing interaction poses a risk of delays in regulatory approval.
Clinical Evidence Challenges: The company emphasizes the need for robust clinical evidence to support regulatory filings and commercial traction. The success of their technology relies on expanding their pool of real-world evidence, which can be challenging and time-consuming.
Market Competition: ENDRA faces competitive pressures in the medical technology landscape, particularly in the liver disease diagnostics market. The need to demonstrate the clinical and economic value of their technology against established standards like MRI adds to this competitive risk.
Financial Stability: ENDRA reported a net loss of $10.1 million for 2023 and has cash and cash equivalents of $2.8 million. The company is evaluating alternatives to raise capital, indicating potential financial instability and the risk of insufficient funds for future operations.
Supply Chain and Operational Risks: The company is expanding its clinical partner sites and engaging in new studies, which may introduce operational risks related to supply chain management and the execution of clinical trials.
Market Adoption: The success of ENDRA's technology in the market is contingent upon achieving commercial sales and acceptance among clinicians, which can be influenced by various external factors including market dynamics and healthcare policies.
Clinical Partner Sites Activation: Activating new clinical partner sites in target markets to build clinical evidence for regulatory and commercial success.
FDA De Novo Application: Advancing FDA De Novo application for TAEUS through collaboration with the agency.
Commercial Position Strengthening: Developing new and nurturing existing relationships with clinicians and maintaining awareness-building activities.
Market Opportunities: Exploring new opportunities to license intellectual property and expand applications of TAEUS beyond liver.
Intellectual Property Expansion: Aggressively expanding global intellectual property portfolio with 16 new patents issued in 2023.
2024 Clinical Evidence: Building clinical evidence through new sites and studies, including a study at King's College Hospital in the UK.
FDA Submission Progress: Anticipating a meeting with the FDA in Q2 2024 to address open items related to De Novo submission.
Commercial Sales Expectations: Expecting to achieve commercial sales with early adopters in Europe in 2024.
Market Expansion: Exploring opportunities in the U.S. bariatric and obesity management market.
Financial Position: Evaluating alternatives to raise capital for future funding needs.
Share Repurchase Program: ENDRA Life Sciences did not mention any share repurchase program during the call.
Dividend Program: ENDRA Life Sciences did not discuss any dividend program during the call.
The earnings call highlights several concerns: regulatory, financial, and market risks are significant, with a declining stock price and cash runway issues. The public offering and reverse stock split indicate financial distress. While operating expenses have decreased, this may impact capabilities. The Q&A revealed unclear guidance on FDA timelines, adding uncertainty. Despite some strategic initiatives, the overall sentiment is negative, suggesting a potential stock price decline of -2% to -8%.
The earnings call presents a mixed picture. Financial performance shows a reduction in net loss and operating expenses, but the cash position is weak. The Q&A highlights progress in clinical partnerships and commercialization plans, but uncertainties in FDA approval and lack of financial guidance raise concerns. The absence of new partnerships or positive guidance adjustments tempers optimism, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
